Key Trends Reshaping the Dengue Vaccine Market: Advancements In Dengue Tetravalent Vaccines Enhance Comprehensive Protection Against All Serotypes Industry Transformation

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Dengue Vaccine Market Size Growth Forecast: What to Expect by 2025?
In recent times, there has been a swift growth in the dengue vaccine market size. The estimates predict a rise from $0.64 billion in 2024 to $0.72 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The previous growth can be credited to factors such as enhanced travel and urban development, heightened demand for efficient vaccines, growing numbers in overseas travel exposure, improvements in healthcare services, and an upswing in large-scale vaccinations.

How Will the Dengue Vaccine Market Size Evolve and Grow by 2029?
The market for dengue vaccines is predicted to experience substantial growth in the coming years, anticipated to reach $1.14 billion in 2029, propelled by a compound annual growth rate (CAGR) of 12.3%. Several factors can be credited for this growth in the projection period, including a rise in dengue cases, increased efforts by numerous organizations, a surge in clinical trials, and heightened focus on developing multi-strain and tetravalent vaccine formulations. Key trends in the projected period encompass growing demand for preventive vaccines, progresses in vaccine technology, the evolution of combination vaccines, an uprise in research and clinical trials for novel vaccine candidates, and emphasis on enhancing vaccine effectiveness and safety.

View the full report here:
https://www.thebusinessresearchcompany.com/report/dengue-vaccine-global-market-report

What Drivers Are Propelling the Growth of Dengue Vaccine Market Forward?
An increase in dengue fever instances is predicted to drive the expansion of the dengue vaccine markets in the future. The Aedes aegypti mosquito is responsible for spreading dengue fever, a viral infection characterized by high fever, severe headaches, joint pains, and skin rashes. Climatic changes, urbanization, ineffective mosquito control methods, and virus evolution have all contributed to an increase in dengue fever cases. The dengue vaccine functions by stimulating the immune system to recognize and fight the dengue virus. It mitigates the severity of the infection and lowers the possibility of grave complications, which in turn reduces the number of both cases and hospital admissions. For example, as per the World Health Organization based in Switzerland, dengue cases in the Americas exceeded 7 million in April 2024, a significant jump from the 4.6 million cases reported in 2023. Thus, the escalating dengue fever instances are boosting the growth of the dengue vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19026&type=smp

Which Emerging Trends Are Transforming the Dengue Vaccine Market in 2025?
Major companies in the dengue vaccine market are endeavoring to formulate advanced vaccine versions like the dengue tetravalent vaccine, which aims for total defense against the four known serotypes of the dengue virus in a single dosage. The vaccine guarantees protection against all four serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), providing an all-inclusive safeguard against dengue fever. For instance, Takeda Pharmaceutical Company, based in Japan, attained the approval of the European Commission (EC) in December 2022 for the use of QDENGA vaccine in people aged four and above. QDENGA is a live-attenuated vaccine, largely employed in countries with a high prevalence of dengue, designed to guard against the disease. It uses a weakened form of the dengue serotype 2 virus as the genetic basis for the other three serotypes. It is dispensed in two 0.5mL doses at 0 and 3 months, and is meant for individuals aged four and above. A Phase 3 study revealed that Qdenga has about an 80.2% effectiveness against dengue, and notably reduces hospitalization rates. Its duration of protection, at approximately 4.5 years, outlasts many other vaccines.

What Are the Key Segments in the Dengue Vaccine Market?
The dengue vaccinemarket covered in this report is segmented -

1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users

Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19026&type=smp

Who Are the Key Players Shaping the Dengue Vaccine Market's Competitive Landscape?
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

What Geographic Markets Are Powering Growth in the Dengue Vaccine Market?
Asia-Pacific was the largest region in the dengue vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19026

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.